知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.047 秒)

    Cross-species-specific single domain bispecific single chain antibody
    1.
    发明授权
    Cross-species-specific single domain bispecific single chain antibody 有权

    公开(公告)号：US10981998B2

    公开(公告)日：2021-04-20

    申请号：US13122280

    申请日：2009-10-01

    申请人： Peter Kufer ,  Tobias Raum ,  Roman Kischel ,  Ralf Lutterbüse ,  Patrick Hoffman ,  Matthias Klinger ,  Doris Rau ,  Susanne Mangold

    发明人： Peter Kufer ,  Tobias Raum ,  Roman Kischel ,  Ralf Lutterbüse ,  Patrick Hoffman ,  Matthias Klinger ,  Doris Rau ,  Susanne Mangold

    IPC分类号： C07K16/28

    摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ϵ (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

    PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA
    4.
    发明申请
    PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 有权
    具有抗溶性CEA的药物抗体组合物

    公开(公告)号：US20120121600A1

    公开(公告)日：2012-05-17

    申请号：US13324823

    申请日：2011-12-13

    申请人： Doris RAU ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    发明人： Doris RAU ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/32

    CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732

    摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” or (ii) a CDR-H1 having the amino acid sequence “TYAMH” and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY”. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.

    摘要翻译： 本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有 氨基酸序列“SYWMH”和具有氨基酸序列“FIRNKANGGTTEYAASVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3或（ii）具有氨基酸序列“TYAMH”的CDR-H1和 具有氨基酸序列“LISNDGSNKYYADSVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3。 此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

    PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA
    6.
    发明申请
    PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 审中-公开
    具有抗溶性CEA的药物抗体组合物

    公开(公告)号：US20090226444A1

    公开(公告)日：2009-09-10

    申请号：US12095952

    申请日：2006-12-21

    申请人： Doris Rau ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    发明人： Doris Rau ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    IPC分类号： C07K16/30 ,  C12P21/08 ,  C12N15/85 ,  A61K39/395 ,  A61K48/00 ,  A61K31/7088 ,  A61P35/04

    CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732

    摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.

    摘要翻译： 本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有 氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO： （SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。 此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

    Pharmaceutical antibody compositions with resistance to soluble CEA
    9.
    发明授权
    Pharmaceutical antibody compositions with resistance to soluble CEA 有权
    具有抗CEA抗性的药物抗体组合物

    公开(公告)号：US08901278B2

    公开(公告)日：2014-12-02

    申请号：US13324823

    申请日：2011-12-13

    申请人： Doris Rau ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    发明人： Doris Rau ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    IPC分类号： C07K16/30 ,  A61K39/00

    CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732

    摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.

    摘要翻译： 本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有 氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO： （SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。 此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。